Theracryf Plc
TCF.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -100% | -10.4% | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | -£0 | £0 | £0 | -£0 |
| % Margin | – | 97.2% | 97.1% | – |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | -899% | -1,147.1% | – |
| Other Income/Exp. Net | £0 | -£0 | £0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | £0 | -£0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | -792.2% | -914.7% | – |
| EPS | -0.004 | -0.011 | -0.015 | -0.01 |
| % Growth | 68.4% | 22.4% | -48.5% | – |
| EPS Diluted | -0.004 | -0.011 | -0.015 | -0.01 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | – | -896.2% | -1,129.6% | – |